{
    "clinical_study": {
        "@rank": "87543", 
        "brief_summary": {
            "textblock": "The long-range goal of this ongoing research program is to find more effective treatments\n      for alcohol dependence by combining medication with the appropriate psychosocial support.\n      This proposal has three specific aims: (1) to compare the effectiveness of naltrexone\n      (Revia) in three types of treatment settings; (2) to assess the effects of psychosocial\n      support on medication compliance and treatment retention; and (3) to investigate the\n      individual characteristics that may predict who is likely to benefit from additional\n      psychosocial support versus simple medication management."
        }, 
        "brief_title": "Naltrexone Treatment of Alcohol Dependence", 
        "completion_date": "January 2003", 
        "condition": "Alcoholism", 
        "condition_browse": {
            "mesh_term": "Alcoholism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Meets criteria for current diagnosis of alcohol dependence.\n\n          -  Subjects used more than 15 standard alcohol drinks (average)/week with at least 1 day\n             of 5 or more drinks in the past 30 days.\n\n          -  Successful completion of medical detoxification.\n\n          -  Lives within a commutable distance to the Treatment Research Center and agrees to\n             follow-up visits.\n\n          -  Understands and signs the informed consent.\n\n        Exclusion Criteria:\n\n          -  Current diagnosis of any substance dependence other than alcohol, nicotine, or\n             marijuana.\n\n          -  Evidence of opiate use in the past 30 days.\n\n          -  Current treatment with psychotropic medications, including disulfiram (Antabuse)\n             (excluding short-term use of benzodiazepines for detoxification).\n\n          -  History of unstable or serious medical illness, including need for opioid analgesics.\n\n          -  Severe physical or medical illnesses such as AIDS, active hepatitis, significant\n             hepatocellular injury as evidenced by elevated bilirubin levels, and current severe\n             psychiatric symptoms.\n\n          -  Use of an investigation medication in the past 30 days.\n\n          -  Female subjects who are pregnant, nursing, or not using reliable method of\n             contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "240", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000452", 
            "org_study_id": "NIAAAVOL07517"
        }, 
        "intervention": [
            {
                "intervention_name": "naltrexone (Revia)", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Compliance Enhancement Tech.", 
                "intervention_type": "Behavioral"
            }, 
            {
                "intervention_name": "Cognitive Behavior Therapy", 
                "intervention_type": "Behavioral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Naltrexone"
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Treatment Research Center, University of Pennsylvania"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 4", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000452"
        }, 
        "source": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2004"
    }, 
    "geocoordinates": {
        "Treatment Research Center, University of Pennsylvania": "39.952 -75.164"
    }
}